Vir Biotechnology (VIR) Assets Average (2019 - 2026)
Vir Biotechnology (VIR) posted Assets Average of $1.0 billion for Q1 2026, little changed sequentially from $1.0 billion in Q4 2025, and down 25.06% YoY from $1.4 billion in Q1 2025.
Vir Biotechnology (VIR) Assets Average (2019 - 2026) Analysis & Trends
Vir Biotechnology has reported Assets Average for 8 years, with the latest figure at $1.0 billion in Q1 2026.
- Quarterly Assets Average fell 25.06% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 25.06% YoY) and the FY2025 annual result came in at $1.2 billion, down 27.62% from the prior year.
- Assets Average steadied at $1.0 billion in Q1 2026 per VIR's latest filing, from $1.0 billion in the prior quarter.
- Over five years, Assets Average peaked at $2.8 billion in Q2 2022 and troughed at $1.0 billion in Q4 2025.
- A 5-year average of $1.9 billion and a median of $1.9 billion in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average soared 151.06% in 2022, then sank 32.1% in 2024.
- Over 5 years, Assets Average stood at $2.7 billion in 2022, then dropped by 27.9% to $2.0 billion in 2023, then fell by 26.91% to $1.4 billion in 2024, then sank by 30.2% to $1.0 billion in 2025, then climbed by 0.3% to $1.0 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $1.0 billion, $1.0 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 1.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Bn |
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 1.25 Bn |
| Mar 31, 2025 | 1.35 Bn |
| Dec 31, 2024 | 1.45 Bn |
| Sep 30, 2024 | 1.58 Bn |
| Jun 30, 2024 | 1.73 Bn |
| Mar 31, 2024 | 1.86 Bn |
| Dec 31, 2023 | 1.98 Bn |
| Sep 30, 2023 | 2.14 Bn |
| Jun 30, 2023 | 2.45 Bn |
| Mar 31, 2023 | 2.73 Bn |
| Dec 31, 2022 | 2.75 Bn |
| Sep 30, 2022 | 2.66 Bn |
| Jun 30, 2022 | 2.75 Bn |
| Mar 31, 2022 | 2.42 Bn |
| Dec 31, 2021 | 1.58 Bn |
| Sep 30, 2021 | 1.13 Bn |